Posted by Michael Wonder on 14 Apr 2024
Cost based pricing for innovative medicines Is unviable and harmful
12 April 2024 - Barber et al. just published a fundamentally flawed study on diabetes medicines in JAMA Network Open.
This study wrongly suggests that cost-based pricing accurately values innovative on patent medicines, distracts from serious policymaking, and fuels political grandstanding by politicians such as Senator Bernie Sanders.
